Eleven Biotherapeutics Inc (EBIO) Shares Drop Over 77 Percent

Eleven Biotherapeutics Inc (NASDAQ:EBIO)’s conjunctivitis treatment failed late-stage trials, sending shares of the stock plunging over 77 percent. The company was confident it would see good results from the drug, EBI-005. However, it failed to show results in the treatment of ocular itching.

Related Stories

• From Glut to Growth: Charting the Path of the Rising Lithium Market

• Biotech's Developments in Race Against Rising Cancer Rates Revealed

• Cheniere Subsides on Quarterly Figures

• Haoxi Picks on Ad Contract

• Amgen Scraps Weight-Loss Pill